Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in France / NCT07613541
Starting soon Observational

Translation and Cultural Adaptation of the Erasmus Modified Nottingham Sensory Assessment Scale for the Lower Limb in Acquired Brain Injury Into French

NCT07613541 · tracked via the Priya Life Science France tracker
Sponsor
University Hospital, Toulouse
Phase
Observational
Started
2026-06
Last updated
2026-05-29

Condition(s) studied

Adults With Acquired Brain Injury

Investigational drug(s) / intervention(s)

French Erasmus modified Nottingham Sensory Assessment scaleSelf-Reported Somatosensory Sensations questionnaireSensitive digital scale

French Erasmus modified Nottingham Sensory Assessment scale: Clinical evaluation of somatosensation of the lower limbs in French

Self-Reported Somatosensory Sensations questionnaire: Somatosensory sensation data

Sensitive digital scale: Sensitive digital assessment data

Study summary

There is a lack of validated and standardized tools in French for assessing somatosensory perception in adults with brain injuries. The only validated tool in French is the Fugl-Meyer Scale for Sensorimotor Recovery after a Stroke, which assesses only light touch sensitivity in two areas of the arm and leg, as well as proprioception for eight joints. The Erasmus Modified Nottingham Sensory Assessment (EmNSA) offers a detailed assessment of limb somatosensory perception in English. The upper limb (UL) version has been validated in French. The lower limb component remains to be translated and culturally adapted. This cross-cultural translation and adaptation project aims to validate this tool for a comprehensive clinical assessment of somatosensory deficits, applicable in both clinical practice and research. The project aims to validate the study of the metrological qualities (validity and reliability of the scale) of the French version of the EmNSA for the lower limbs.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion criteria: * Patient with an acquired brain injury attested by brain imaging (CT scan or MRI) of more than seven days * Sufficient comprehension ability to participate in the study * Patients receiving care in the routine care pathway, as part of rehabilitation or functional assessments available for 6 weeks minimum and 12 weeks maximum * Ability to hold attention for at least 30 minutes * Aphasia Severity Scale score of 4 or higher * Anosognosia Assessment (from the Unilateral Neglect Assessment Battery) score of 1 or lower Exclusion criteria: * Patient with peripheral neurological pathology * Severe communication disorders with a score of less than 4 on the Aphasia Severity Scale * Anosognosia Assessment (from the Unilateral Neglect Assessment Battery) score of 2 or higher * Major attention disorders making it impossible to take stock * Patient under guardianship

Primary outcome measure(s)

  • Inter-rater reproducibility — Day 0 and day 7
    The intraclass correlation coefficient will be evaluated based on the results of the EmNSAMI measurements, obtained by 2 independent evaluators (E1 and E2 or E3; therapists with expertise in the evaluation of patients with acquired brain injury).

Trial sites (1)

FacilityCityRegionStatus
Service des Explorations Fonctionnelles Physiologiques (Pôle 32) - Hôpital Purpan, Place du Dr Baylac Toulouse Occitanie

More University Hospital, Toulouse trials in France

Intragastric Balloon in Obese Patients With Uncontrolled Asthma Recruiting
Study of the Interprofessional Reproducibility of a Clinical Observation Scale for the Development of Very Premature Infants Starting soon
Avacopan Added to Standard-of-care Therapy in ANCA-associated Vasculitis With Severe Kidney Involvement Starting soon
LUng and Cardiac Ultrasound for REspiratory Distress in ElDerly Recruiting
Semantic Rehabilitation for Patients With Primary Progressive Semantic Aphasia Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07613541 on ClinicalTrials.gov ↗ ← All trials in France